Imunon Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
41.5%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$3.01next fiscal year
Monitoring Framework
Key Performance Indicators
OVATION 3 Phase 3 Trial Enrollment Progress QuarterlyTarget: Complete enrollment by Q1 2029
Cash and Cash Equivalents Quarterly4.8MTarget: Secure strategic financing to extend runway
Quarterly Net Loss Quarterly-4.3MTarget: Maintain cost discipline under strategic reorganization
Watch Items
- OVATION 3 Interim Efficacy AnalysesTrigger: Interim data readouts enabling potential early stopping or BLA filingAction: Prepare Biologics License Application (BLA) for the HRD+ population if triggers are met
- Cash Runway and LiquidityTrigger: Cash balance falling below $3.0 millionAction: Utilize ATM equity facility or secure non-dilutive/dilutive strategic financing
- PlaCCine Platform Clinical Progress (IMNN-101)Trigger: Initiation of subsequent clinical phases or partner collaborationsAction: Evaluate business development opportunities and licensing deals
Research as of 20 Jun 2026